Related Experiment Video
Updated: Jun 10, 2026
06:15
Anterior High-Resolution Optical Coherence Tomography in the Diagnosis and Therapeutic Monitoring of Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
Periocular lentigo maligna treated with imiquimod
Jennifer O'Neill1, Dominic Ayers, John Kenealy
1Department of Plastic Surgery, Frenchay Hospital, Bristol, UK. jenniferoneill@hotmail.com
The Journal of Dermatological Treatment
|July 30, 2010
Summary
Topical imiquimod 5% cream effectively treated a challenging eyelid borderline lentigo maligna. This non-surgical approach led to complete lesion resolution and no recurrence over a 3-year follow-up period.
Area of Science:
- Dermatology
- Oncology
Background:
- Topical imiquimod 5% cream is an established treatment for various eyelid skin conditions.
- Eyelid basal cell carcinoma, Bowen's disease, and lentigo maligna have shown positive responses to imiquimod therapy.
Observation:
- A case of borderline lentigo maligna on the eyelid presented treatment challenges with conventional surgery.
- The patient opted for topical imiquimod 5% cream due to personal reasons for deferring surgery.
Findings:
- Complete resolution of the borderline lentigo maligna lesion was achieved using topical imiquimod 5% cream.
- No recurrence of the lesion was observed during a 3-year follow-up period after treatment.
Implications:
- Topical imiquimod 5% cream offers a viable non-surgical treatment option for difficult-to-treat eyelid lentigo maligna.
- Further investigation into the use of imiquimod for periocular lentigo maligna is warranted.
